A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

Triple-negative breast cancer (TNBC) accounts for about 20% of breast cancers, is poorly differentiated, progresses rapidly, and frequently recurs, making it the subtype with the worst prognosis. Owing to the absence of actionable receptors on tumor cells, chemotherapy has historically been the mainstay of TNBC treatment. With advances in basic research, more immune checkpoint inhibitors (ICIs) targeting distinct pathways have entered clinical use. Avellutolimab (QL1706) combines two engineered monoclonal antibodies-anti-PD-1 and anti-CTLA-4-in a fixed \~2:1 ratio. By blocking PD-1, it inhibi

Trial Details

NCT ID
NCT07178171
Phase
PHASE1
Sponsor
Xijing Hospital
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • QL1706 (bispecific antibody targeting PD-1 and CLTA-4)
  • Pirarubicin
  • Nab-paclitaxel
  • Carboplatin (AUC 5)
  • Cyclophosphamide
Locations (sample)
  • Xi'an, Shaanxi, China|34.25833,108.92861

Key Eligibility Criteria

  • Female patients aged ≥18 and ≤70 years with newly diagnosed invasive breast cancer.
  • Triple-negative breast cancer (TNBC) with clinical stage cT2-T4 and cN0-cN3.
  • Unilateral disease.
  • No prior chemotherapy or immunotherapy for invasive breast cancer.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →